Download PDF
Arzneimittelforschung 2008; 58(2): 81-85
DOI: 10.1055/s-0031-1296472
Antiemetics · Gastrointestinal Drugs · Urologic Drugs
Editio Cantor Verlag Aulendorf (Germany)

Effects of D-004, a Lipid Extract from the Royal Palm (Roystonea regia) Fruits, Tamsulosin and their Combined Use on Urodynamic Changes Induced with Phenylephrine in Rats

Maria de Lourdes Arruzazabala
Center of Natural Products, National Center for Scientific Research, Havana City, Cuba
,
Vivian Molina
Center of Natural Products, National Center for Scientific Research, Havana City, Cuba
,
Rosa Más
Center of Natural Products, National Center for Scientific Research, Havana City, Cuba
,
Daisy Carbajal
Center of Natural Products, National Center for Scientific Research, Havana City, Cuba
› Author Affiliations
Further Information

Publication History

Publication Date:
15 December 2011 (online)

    Permissions and Reprints

Abstract

5-α-Reductase inhibitors, α1-adrenoreceptors blockers and herbal drugs, like lipid extracts from saw palmetto fruits, are used to treat benign prostatic hyperplasia (BPH). D-004, a lipid extract from the Royal palm fruits, prevented prostate hyperplasia (PH) induced with testosterone and the atypical PH induced with phenylephrine (PHE) in the rat, its effect in this last model being comparable to that of saw palmetto, but lesser than that of tamsulosin (CAS 106133-20-4). It was investigated whether single doses of D-004, tamsulosin and their combined therapy can prevent urodynamic changes induced with PHE in the rat. Firstly, the effects of PHE on rat volume voided per micturition (VM) were explored in rats that were distributed in three groups: a negative control and two groups injected s. c. with PHE (5 and 10 mg/kg, respectively). In the other two experiments, rats were distributed in four groups: a negative control and three groups injected with PHE (a positive control and two groups treated with either tamsulosin 0.05 and 0.1 mg/kg, or D-004 400 and 800 mg/kg. In another experiment, the effects of the combined therapy were assessed using four groups: a negative control, a positive control and three groups treated orally with tamsulosin 0.05 mg/kg, D-004 400 mg/kg or D-004 400 mg/kg + tamsulosin 0.05 mg/kg, respectively. Sixty min later, all rats (except negative controls) were injected s. c. with PHE (5 mg/kg), and all (including the negative controls) received a fluid-loading dose. Thirty min later, they were placed in metabolic cages and the VM was measured for 1 h. The VM was significantly reduced with PHE (5 and 10 mg/kg), the high dose producing anuria in 50% of the rats. The reduction of VM was significantly and dose-dependently prevented with tamsulosin (0.05 and 0.1 mg/kg) (42.9% and 60.3%, respectively) and with D-004 (400 and 800 mg/kg) (25.2% and 43.1%, respectively). The inhibition reached (70.9%) with the combined therapy was greater than that reached with each monotherapy and also greater than the sum (56.8%) of the inhibitions reached with tamsulosin (35%) or D-004 (21.8%) alone. In conclusion, tamsulosin (0.05 and 0.1 mg/kg) and D-004 (400–800 mg/kg) dose-dependently inhibited the VM reduction induced with PHE, their combined therapy producing the greater effects.

Key words

CAS 106133-20-4 - D-004, effect on urodynamic changes, rat - Omnic® - Royal palm fruits, lipid extract - Tamsulosin, effect on urodynamic changes, rat - Urologic drugs
 

  • References

  • 1 Barry MJ, Roehrborn CG. Benign prostatic hyperplasia. BMJ. 2001; 323: 1042-1046
    PubMedGoogle Scholar
  • 2 Yamada S, Ashizawa N, Ushijima H, Nakayama K, Hayashi E, Honda K. Alpha1-adrenoceptors in human prostate: Characterization and alteration in benign prostatic hypertrophy. J Pharmacol Exp Ther. 1987; 242: 326-330
    PubMedGoogle Scholar
  • 3 Michel MC, Taguchi K, Schafers RS, Williams TJ, Clarke DE, Ford AP. a1-Adrenoceptors subtypes in the human cardiovascular and urogenital systems. Adv Pharmacol. 1998; 42: 394-398
    PubMedGoogle Scholar
  • 4 Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of a1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol. 1999; 36: 1-13
    PubMedGoogle Scholar
  • 5 Oelke M, Hofner K, Berges RR, Jonas U. Drug therapy of benign prostatic hyperplasia syndrome with alpha 1-receptors blockers. Basic principles and clinical results. Urologe A. 2002; 41: 425-441
    CrossrefPubMedGoogle Scholar
  • 6 Price DT, Schwinn DA, Lomansney JW, Allen LF, Caron MG, Lefkowitz RJ. Identification, quantification, and localization of mRNA for three distinct 1 adrenergic receptor subtypes in human prostate. J Urol. 1993; 150: 546-551
    PubMedGoogle Scholar
  • 7 Moriyama N, Kurimoto S, Horie S, Nasu K, Tanaka T, Yano K et al. Detection of 1-adrenoceptor subtypes in human hypertrophied prostate by in situ hybridization. Histochem J. 1996; 28: 283-288
    CrossrefPubMedGoogle Scholar
  • 8 Marshall I, Burt RP, Chapple CR. Noradrenaline contractions of human prostate mediated by alfa 1A (1c) adrenoceptor subtype. Br J Pharmacol. 1995; 115: 781-786
    CrossrefPubMedGoogle Scholar
  • 9 Hatano A, Takahashi H, Tamaki M, Komeyama T, Koizumi T, Takeda M. Pharmacological evidence of distinct 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol. 1994; 113: 723-728
    CrossrefPubMedGoogle Scholar
  • 10 Kawabe K. Efficacy and safety of tamsulosin in the treatment of benign prostatic hyperplasia. Br J Urol. 1995; 76 (Suppl1) 63-67
    PubMedGoogle Scholar
  • 11 Na YJ, Guo YL, Gu F-L. Clinical comparison of selective and non-selective alpha IA-adreno receptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. J Med. 1998; 29: 289-304
    PubMedGoogle Scholar
  • 12 Akiyama K, Hora M, Tatemichi S, Masuda N, Nakamura S, Yamagishi R et al. KMD-3213, a uroselective and long-acting adrenoceptor antagonist, tested in a novel rat model. J Pharm Exp Ther. 1999; 291: 81-91
    PubMedGoogle Scholar
  • 13 Lowe FC, Dreikorn K, Borkowski A, Braeckman J, Denis L, Ferrari P et al. Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH. Prostate. 1998; 37: 187-193
    CrossrefPubMedGoogle Scholar
  • 14 Plosker GL, Brodgen RN. Serenoa repens (Permixon): A review of its pharmacological and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging. 1996; 9: 379-395
    CrossrefPubMedGoogle Scholar
  • 15 Wilt T, Ishani A, Mac Donald R, Mulrow C, Lau J. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2000; 3 CD001523
    PubMedGoogle Scholar
  • 16 Aliaev GIu, Vinarov AZ, Lokshin KL, Spivak LG. Five-years experience in treating with prostatic hyperplasia patients with permixon (Serenoa repens Pierre Fabre Medicament). Urologia. 2002; 1: 23-25
    PubMedGoogle Scholar
  • 17 Gordon AE, Shaughnessy AF. Saw palmetto for prostate disorders. Am Fam Physician. 2003; 67: 1281-1283
    PubMedGoogle Scholar
  • 18 Carraro CJ, Raynaud PJ, Koch G, Chirsholm DG, Di Silverio F, Teillac P et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate. 1996; 29: 231-240
    CrossrefPubMedGoogle Scholar
  • 19 Debruyne F, Koch G, Boyle P, Da Silva FC, Gillenwater JG, Hamdy CF et al. Groupe d’étude PERMAL. Comparison of phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: 1 year randomized international study. Prog. Urol. 2002; 2: 384-392
    PubMedGoogle Scholar
  • 20 Willetts KE, Clements MS, Champion S, Champion S, Ehsman S, Eden JA. Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. BJU Int. 2003; 92: 267-270
    CrossrefPubMedGoogle Scholar
  • 21 Bent S, Kane C, Shinohara K, Neuhaus J, Hudes ES, Goldberg H et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med. 2006; 354: 557-566
    CrossrefPubMedGoogle Scholar
  • 22 Bombardelli E, Morazzoni P. Serenoa repens (Bartram) JK Small. Fitoterapia. 1997; 68: 99-113
    PubMedGoogle Scholar
  • 23 Raynaud JP, Cousse H, Martin PM. Inhibition of type 1 and 2 5 alpha reductase activity by free fatty acids active ingredients of Permixon. J Steroid Biochem. 2002; 82: 233-239
    PubMedGoogle Scholar
  • 24 Goepel M, Dihn L, Mitchell A et al. Do saw palmetto extracts block human a1-adrenoceptors subtypes in vivo?. Prostate. 2001; 46: 226-232
    CrossrefPubMedGoogle Scholar
  • 25 Goepel M, Hecker U, Krege HS Rubben, Michel MC. Saw palmetto extracts potently and non-competitively inhibits human alpha 1 adrenoceptors in vitro. Prostate. 1999; 38: 208-215
    CrossrefPubMedGoogle Scholar
  • 26 Arruzazabala ML, Carbajal D, Mas R Molina V, Rodriguez E, Gonzalez V. Preventive effects of D-004 a lipid extract from Cuban royal palm (Rostoynea regia) fruits on prostate hyperplasia induced with testosterone on intact and castrated rodents. Drugs Exp Clin Res. 2004; XXX: 227-234
    PubMedGoogle Scholar
  • 27 Carbajal D, Arruzazabala ML, Mas R, Molina V, Rodriguez E, Gonzalez V. Effect of D-004, a lipid extract from Cuban royal palm fruit, on inhibiting prostate hyperplasia induced with testosterone and dihydrotestosterone in rats. Curr Ther Res Clin Exp. 2004; 65: 505-514
    CrossrefPubMedGoogle Scholar
  • 28 Carbajal D, Molina V, Mas R, Arruzazabala ML. Therapeutic effect of D-004, a lipid extract from Roystonea regia fruits, on prostate hyperplasia induced in rats. Drugs Exp Clin Res. 2005; 31: 193-197
    PubMedGoogle Scholar
  • 29 Noa M, Arruzazabala ML, Carbajal D, Mas R, Molina V. Effect of D-004, a lipid extract from Cuban royal palm fruit, on histological changes of prostate hyperplasia induced with testosterone in rats. Int J Tiss React. 2005; XXVII: 203-211
    PubMedGoogle Scholar
  • 30 Pérez Y, Menéndez R, Mas R, González R. In vitro effect of D-004, a lipid extract from the Cuban Royal palm (Roystonea regia) fruits, on the activity of prostate steroid 5-alpha reductase. Curr Ther Res Clin Exp. 2006; 67: 396-405
    CrossrefPubMedGoogle Scholar
  • 31 Arruzazabala ML, Más R, Carbajal D, Molina V. Effect of D-004, a lipid extract from Cuban royal palm fruit, on in vitro and in vivo effects mediated by a adrenoceptors in rat. Drugs R&D. 2005; 6: 281-289
    CrossrefPubMedGoogle Scholar
  • 32 Arruzazabala ML, Más R, Molina V, Noa M, Carbajal D, Mendoza N. Effect of D-004, a lipid extract from the Cuban royal palm fruit on atypical prostate hyperplasia induced by phenylephrine in rats. Drugs R&D. 2006; 7: 233-241
    CrossrefPubMedGoogle Scholar
  • 33 Constantinou CE. Influence of hormone treatment on prostate growth and micturition characteristics of the rat. Prostate. 1996; 29: 30-5
    PubMedGoogle Scholar
  • 34 Golomb E, Kruglikova A, Dvir D, Parnes N. Abramovici A. Induction of atypical prostatic hyperplasia in rats by sympathomimetic stimulation. Prostate. 1998; 34: 214-221
    CrossrefPubMedGoogle Scholar
  • 35 Gutierrez M, Garcia de, Boto MJ, Cantabrana B, Hidalgo A. Mechanisms involved in the spasmolytic effect of extracts from Sabal serrulata fruit on smooth muscle. Gen Pharmacol. 1996; 27: 171-176
    CrossrefPubMedGoogle Scholar
  • 36 Odenthal KP, Rauwald HW. Lipophilic extract from Sabal serrulata inhibits contractions in smooth muscle tissue. Aktuelle Urologie. 1996; 27: 152-157
    Article in Thieme ConnectPubMedGoogle Scholar